The Korean journal of internal medicine

  • 제26권3호
  • /
  • Pages.294-303
  • /
  • 2011
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Clinical Outcomes of Hydrophilic and Lipophilic Statins in Patients with Acute Myocardial Infarction

  • Kim, Min-Chul (The Heart Center of Chonnam National University Hospital) ;
  • Ahn, Young-Keun (The Heart Center of Chonnam National University Hospital) ;
  • Jang, Su-Young (The Heart Center of Chonnam National University Hospital) ;
  • Cho, Kyung-Hoon (The Heart Center of Chonnam National University Hospital) ;
  • Hwang, Seung-Hwan (The Heart Center of Chonnam National University Hospital) ;
  • Lee, Min-Goo (The Heart Center of Chonnam National University Hospital) ;
  • Ko, Jum-Suk (The Heart Center of Chonnam National University Hospital) ;
  • Park, Keun-Ho (The Heart Center of Chonnam National University Hospital) ;
  • Sim, Doo-Sun (The Heart Center of Chonnam National University Hospital) ;
  • Yoon, Nam-Sik (The Heart Center of Chonnam National University Hospital) ;
  • Yoon, Hyun-Ju (The Heart Center of Chonnam National University Hospital) ;
  • Kim, Kye-Hun (The Heart Center of Chonnam National University Hospital) ;
  • Hong, Young-Joon (The Heart Center of Chonnam National University Hospital) ;
  • Park, Hyung-Wook (The Heart Center of Chonnam National University Hospital) ;
  • Kim, Ju-Han (The Heart Center of Chonnam National University Hospital) ;
  • Jeong, Myung-Ho (The Heart Center of Chonnam National University Hospital) ;
  • Cho, Jeong-Gwan (The Heart Center of Chonnam National University Hospital) ;
  • Park, Jong-Chun (The Heart Center of Chonnam National University Hospital) ;
  • Kang, Jung-Chaee (The Heart Center of Chonnam National University Hospital)
  • 발행 : 2011.09.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: A controversy exists about which statin is preferable for patients with acute myocardial infarction (AMI), and clinical impacts of different statins according to lipophilicity have not been established. Methods: The 1,124 patients with AMI included in the present study were divided into hydrophilic- and lipophilic-statin groups. In-hospital complications (defined as death, cardiogenic shock, ventricular arrhythmia, infection, bleeding, and renal insufficiency, and other fatal arrhythmias), major adverse cardiac events (MACE), all-cause death, re-myocardial infarction, re-percutaneous coronary intervention (re-PCI), and surgical revascularization were analyzed during a 1-year clinical follow-up. Results: Baseline characteristics were similar between the two groups, and in-hospital complication rates showed no between-group differences (11.7% vs. 12.8%, p = 0.688). Although MACE at the 1- and 6-month clinical follow-ups occurred more in hydrophilic statin group I (1 month: 10.0% vs. 4.4%, p = 0.001; 6 month: 19.9% vs. 14.2%, p = 0.022), no significant difference in MACE was observed at the 1-year follow-up (21.5% vs. 17.9%, p = 0.172). Both statin groups showed similar efficacy for reducing serum lipid concentrations. A Cox-regression analysis showed that the use of a hydrophilic statin did not predict 1-year MACE, all-cause death, AMI, or re-PCI. Conclusions: Although short-term cardiovascular outcomes were better in the lipophilic-statin group, 1-year outcomes were similar in patients with AMI who were administered hydrophilic and lipophilic statins. In other words, the type of statin did not influence 1-year outcomes in patients with AMI.

키워드

참고문헌

  1. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316. https://doi.org/10.1001/jama.292.11.1307
  2. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504. https://doi.org/10.1056/NEJMoa040583
  3. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445. https://doi.org/10.1001/jama.294.19.2437
  4. Lenderink T, Boersma E, Gitt AK, et al. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J 2006;27:1799-1804. https://doi.org/10.1093/eurheartj/ehl125
  5. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278. https://doi.org/10.1016/S0140-6736(05)67394-1
  6. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135. https://doi.org/10.1161/01.CIR.97.12.1129
  7. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-283. https://doi.org/10.1161/01.CIR.103.2.276
  8. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999;33:1294-1304. https://doi.org/10.1016/S0735-1097(99)00018-2
  9. Zile MR. Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. Circulation 2005;112:300-303. https://doi.org/10.1161/CIRCULATIONAHA.105.551887
  10. Yoon HE, Song JC, Hyoung BJ, et al. The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Korean J Intern Med 2009;24:233-237. https://doi.org/10.3904/kjim.2009.24.3.233
  11. Park JS, Kim YJ, Choi JY, et al. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. Korean J Intern Med 2010;25:27-35. https://doi.org/10.3904/kjim.2010.25.1.27
  12. McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol 2003;26(4 Suppl 3):III32-III38. https://doi.org/10.1002/clc.4960261507
  13. Sakamoto T, Kojima S, Ogawa H, et al. Usef ulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI. Circ J 2007;71:1348-1353. https://doi.org/10.1253/circj.71.1348
  14. Kai T, Arima S, Taniyama Y, Nakabou M, Kanamasa K. Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study. Clin Exp Hypertens 2008;30:530-540. https://doi.org/10.1080/10641960802251925
  15. Fujita M, Yamazaki T, Hayashi D, et al. Pleiotropic effects of statins on cardiovascular events in the Japanese Coronary Artery Disease study. Int J Cardiol 2008;129:294-296. https://doi.org/10.1016/j.ijcard.2007.06.054
  16. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-2241. https://doi.org/10.1016/j.jacc.2009.10.015
  17. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Pat ients With Unstable Angina/Non-ST-Elevat ion Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157. https://doi.org/10.1016/j.jacc.2007.11.004
  18. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-1513. https://doi.org/10.1053/euhj.2000.2305
  19. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538. https://doi.org/10.1093/eurheartj/ehm355
  20. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
  21. Glasser SP, Wadley V, Judd S, et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Clin Cardiol 2010;33:280-288. https://doi.org/10.1002/clc.20758
  22. Kato S, Smalley S, Sadarangani A, et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med 2010;14:1180-1193.
  23. Salman H, Bergman M, Djaldetti M, Bessler H. Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomed Pharmacother 2008;62:41-45. https://doi.org/10.1016/j.biopha.2007.07.007
  24. Li YH, Wu HL, Yang YH, Tsai HS, Chao TH. Effect of early versus late in-hospital initiation of statin therapy on the clinical outcomes of patients with acute coronary syndrome. Int Heart J 2007;48:677-688. https://doi.org/10.1536/ihj.48.677
  25. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28. https://doi.org/10.1056/NEJMoa042378
  26. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-678. https://doi.org/10.1161/01.CIR.0000137828.06205.87

피인용 문헌

  1. Statins of high versus low cholesterol‐lowering efficacy and the development of severe renal failure vol.22, pp.6, 2011, https://doi.org/10.1002/pds.3433
  2. Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis vol.2, pp.1, 2011, https://doi.org/10.1186/2046-4053-2-22
  3. Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study vol.7, pp.None, 2011, https://doi.org/10.2147/dddt.s44099
  4. Fusion Imaging–Guided Percutaneous Biopsy of Focal Hepatic Lesions With Poor Conspicuity on Conventional Sonography vol.32, pp.9, 2011, https://doi.org/10.7863/ultra.32.9.1557
  5. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia vol.231, pp.1, 2011, https://doi.org/10.1016/j.atherosclerosis.2013.08.013
  6. Pravastatin But Not Simvastatin Improves Survival and Neurofunctional Outcome After Cardiac Arrest and Cardiopulmonary Resuscitation vol.2, pp.2, 2011, https://doi.org/10.1016/j.jacbts.2017.01.009
  7. Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors vol.9, pp.7, 2011, https://doi.org/10.14740/jocmr3066w
  8. Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome : A Prospective Randomized Trial vol.59, pp.1, 2011, https://doi.org/10.1536/ihj.16-587
  9. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms vol.7, pp.1, 2011, https://doi.org/10.1186/s40035-018-0110-3
  10. Oxidative stress as a possible mechanism of statin-induced myopathy vol.26, pp.3, 2011, https://doi.org/10.1007/s10787-018-0469-x
  11. Suggested clinical approach for the diagnosis and management of ‘statin intolerance’ with an emphasis on muscle‐related side‐effects vol.49, pp.9, 2011, https://doi.org/10.1111/imj.14429
  12. The Different Cardiovascular Outcomes Between Long-Term Efficacy of Hydrophilic and Lipophilic Statin Therapy in Both Asian Diabetic Sexes vol.17, pp.3, 2011, https://doi.org/10.1177/1559325819876766
  13. Protection of renal damage by HMG-CoA inhibitors: A comparative study between atorvastatin and rosuvastatin vol.23, pp.2, 2011, https://doi.org/10.22038/ijbms.2019.38239.9080
  14. Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy vol.12, pp.4, 2020, https://doi.org/10.14740/jocmr4144
  15. Clinical Benefit of Statins in Korean Patients with Acute Myocardial Infarction: Experience of the Korea Acute Myocardial Infarction Registry vol.9, pp.3, 2020, https://doi.org/10.12997/jla.2020.9.3.362
  16. Hydrophilic or Lipophilic Statins? vol.8, pp.None, 2011, https://doi.org/10.3389/fcvm.2021.687585